Hypoxia Proteomics Service

Q: How do you prevent HIF‑α degradation and reoxygenation artifacts during cell harvesting?

HIF‑1α and HIF‑2α subunits possess an extremely short half‑life (<5 minutes) upon exposure to atmospheric oxygen due to rapid PHD reactivation and VHL‑mediated ubiquitination. We implement strict anti‑reoxygenation SOPs: (1) rapid ice‑cold PBS washing (≤15 seconds total) followed immediately by direct on‑plate lysis with SDS‑based denaturing buffers containing protease and phosphatase inhibitors; or (2) cell scraping and lysis conducted directly inside a hypoxia workstation/glove box under matched O₂ tension.

Q: What is the difference between physical hypoxia chambers and chemical hypoxia mimetics?

Physical hypoxia chambers (0.1%–1% O₂) mimic genuine in vivo physiological and pathological low‑oxygen conditions, triggering authentic HIF stabilization, metabolic reprogramming, and translational adaptation. Chemical mimetics (CoCl₂, DMOG, DFO, Roxadustat) stabilize HIF by inhibiting PHDs via iron competition or 2‑oxoglutarate antagonism; however, they cause broad off‑target inhibition of other 2‑oxoglutarate‑dependent dioxygenases (such as histone lysine demethylases / KDMs and TET DNA demethylases). We recommend physical chamber control for physiological accuracy, and provide comparative benchmarking when chemical mimetics are evaluated.

Q: How does proteomics distinguish acute HIF‑1α responses from chronic HIF‑2α signaling?

HIF‑1α and HIF‑2α exhibit distinct temporal dynamics and transcriptional target preferences. HIF‑1α peaks during acute hypoxia (2–12 h) and predominantly drives glycolytic enzyme upregulation (GLUT1, HK2, LDHA, PDK1) and pH regulation (CAIX). In contrast, HIF‑2α accumulates and remains stabilized during chronic hypoxia (24–72+ h), preferentially driving angiogenesis (VEGFA, ANGPTL4), erythropoiesis (EPO), iron transport (TFRC), and cancer stemness (OCT4, SOX2, CXCR4). Our multi‑time‑point DIA proteomic profiling tracks these distinct regulatory waves across time‑course series.

Q: What is the minimum cell number required for hypoxia DIA proteomics?

For standard global DIA whole‑cell proteomics, we recommend 1–5 × 10⁶ cells (yielding 20–50 μg protein), though robust data can be acquired from 2 × 10⁵ cells. For precious samples (e.g., laser‑capture microdissected hypoxic tumor cores, 3D organoid spheroids, or needle biopsies), our high‑sensitivity 4D‑DIA (dia‑PASeF on timsTOF Pro 2) routinely quantifies >5,500+ proteins from as few as 5 × 10⁴ cells (~500 ng protein). For phosphoproteomics, a minimum of 50–100 μg total protein is recommended.

Q: How does proteomics evaluate HIF‑2α inhibitor therapeutics (e.g., Belzutifan / MK‑6482)?

Small‑molecule HIF‑2α allosteric inhibitors (such as Belzutifan in clear cell renal cell carcinoma / ccRCC) disrupt the heterodimerization between HIF‑2α (EPAS1) and HIF‑1β (ARNT), preventing transcription of downstream oncogenic programs. Our platform quantifies proteome‑wide on‑target and off‑target shifts, measuring the selective downregulation of HIF‑2α targets (VEGFA, CCND1, CXCR4, EGLN3) versus unaffected baseline housekeeping proteomes across dose‑ and time‑dependent treatment cohorts.

Q: Can you profile ischemia‑reperfusion (I/R) tissue models?

Yes. We process fresh‑frozen tissues from animal models of acute myocardial infarction, ischemic stroke (MCAO), and renal ischemia‑reperfusion injury. Our multi‑group experimental designs compare Sham, Ischemia (Acute Hypoxia), and Reperfusion (Reoxygenation) phases to dissect protective HIF‑mediated adaptations from oxidative reperfusion damage and inflammatory infiltration.

Q: What sample submission format and project metadata are required?

Samples should be submitted as flash‑frozen cell pellets (washed 2× with ice‑cold PBS), fresh‑frozen tissue pieces (≥20–50 mg), clarified conditioned media, or client‑prepared protein lysates. Please provide project metadata including: (1) species (human/mouse/rat), (2) hypoxia model (O₂ chamber percentage, duration, chemical stabilizers), (3) normoxic/reoxygenation controls, (4) replicate mapping, (5) cell count or protein concentration, and (6) requested analytical layers (global DIA, 4D‑phosphoproteomics, secretome).

Physical O₂ Chamber Control · Anti-Reoxygenation SOP · HIF-1α vs. HIF-2α Switches · Hypoxic Secretomes

Severe hypoxia (≤1% O₂) triggers massive translational arrest that decouples mRNA expression from functional protein abundance by up to 80%, while room-air exposure degrades HIF-α subunits in under five minutes.

Creative Proteomics delivers a dedicated Hypoxia Proteomics Service engineered around strict anti-reoxygenation quenching SOPs. We integrate high-depth DIA, 4D-phosphoproteomics, and secretome profiling to track acute-to-chronic HIF transitions, Warburg glycolytic rewiring, extracellular matrix remodeling, and HIF-targeted therapeutic responses.

Anti-reoxygenation flash-quenching SOP (≤15 s) to preserve native HIF-1α and HIF-2α stabilization without room-air artifacts
Temporal HIF-1α vs. HIF-2α dissection resolving acute glycolytic survival (2–12 h) from chronic angiogenesis and stemness (24–72 h)
Physical hypoxia vs. chemical mimetic benchmarking to differentiate genuine oxygen responses from CoCl₂/DMOG chromatin off-target effects
Dual cellular proteome & secretome profiling capturing intracellular metabolic switches alongside secreted angiogenic drivers (VEGFA, LOX, MMPs)
Microscale capability (from 5×10⁴ cells) via 4D-DIA (dia-PASeF) for microdissected hypoxic tumor cores and needle biopsies

Request a Quote

Why Transcriptomics Fails in Low-Oxygen Biology

Under physiological normoxia (~21% in vitro, 3–7% in vivo physioxia), prolyl hydroxylases (PHD1–3) continuously hydroxylate HIF-1α and HIF-2α, marking them for rapid ubiquitination by the pVHL E3 ligase complex and proteasomal degradation within minutes. When oxygen tension drops below 1% O₂, PHD activity ceases, allowing HIF-α subunits to stabilize, dimerize with HIF-1β (ARNT), and drive transcription.

However, hypoxia simultaneously triggers the integrated stress response—inducing PERK-mediated eIF2α phosphorylation and 4E-BP1/mTORC1 suppression—which shuts down global cap-dependent translation by 70–80%. Consequently, hundreds of transcribed hypoxia-induced mRNAs remain untranslated or sequestered in stress granules, while critical hypoxia effectors (e.g., VEGFA, GLUT1) are translated via cap-independent IRES or uORF mechanisms. mRNA transcript abundance is therefore fundamentally uncoupled from functional protein output during hypoxia.

Quantitative LC-MS/MS proteomics directly quantifies actual steady-state protein levels, active metabolic enzyme complexes, post-translational modifications, and secretomes, providing the ground-truth evidence required for rigorous hypoxia research.

Content Guide

Physical vs. Chemical Hypoxia
HIF-1α to HIF-2α Handover
Research Scenarios & Designs
Anti-Reoxygenation SOP
Analytical & MS Strategies
Sample Requirements
Deliverables & Data Outputs

Methodological Integrity: Physical O₂ Control vs. Chemical Mimetics

Many published hypoxia studies rely on chemical mimetics (CoCl₂, DMOG, DFO, Roxadustat) because they are convenient. However, chemical stabilizers inhibit PHDs by competing with 2-oxoglutarate (2-OG) or displacing catalytic Fe²⁺. This non-specifically inhibits dozens of other 2-OG-dependent dioxygenases—including JmjC-domain histone lysine demethylases (KDMs) and TET DNA methylases—introducing sweeping epigenetic artifacts that do not occur in physiological hypoxia.

Experimental Modality	Mechanism of HIF Stabilization	Analytical Off-Target Risks	Best Used For
Physical Hypoxia Chamber (0.1%–1.0% O₂ Controlled)	Direct oxygen substrate deprivation of PHD1–3 and FIH-1 enzymes.	None; reflects authentic physiological and pathological hypoxia.	Gold-standard mechanistic studies, in vivo translation, and drug response profiling.
CoCl₂ (Cobalt Chloride) (100–300 μM)	Displaces active-site Fe²⁺ and generates reactive oxygen species.	Broad heavy metal toxicity, non-specific lipid oxidation, and KDM inhibition.	High-throughput in vitro pre-screening before physical validation.
DMOG / Roxadustat (2-OG Competitors)	Competitive inhibition of 2-oxoglutarate binding pocket in PHDs.	Broadly inhibits KDMs (KDM2–6) and TET1–3, altering global histone methylation.	Targeted prolyl hydroxylase inhibitor evaluation and erythropoiesis research.
DFO (Deferoxamine) (Iron Chelator, 100 μM)	Depletes intracellular labile Fe²⁺ required for PHD cofactor function.	Severe iron depletion, mitochondrial complex disruption, and cell cycle arrest.	Dissecting iron-dependent regulatory nodes versus oxygen-dependent pathways.

The HIF-1α to HIF-2α Temporal Handover and Metabolic Rewiring

Cellular adaptation to hypoxia is not a static state, but a coordinated four-phase temporal program. Our time-course proteomics platform maps each phase with dedicated quantitative readouts:

Phase 1: Acute Oxygen Sensing (0.5–2 h)

Immediate PHD/FIH inhibition and kinase cascades. Upregulation of AMPK phosphorylation, PDK1-mediated inactivation of pyruvate dehydrogenase (PDH), and stress kinase signaling (PERK, p38 MAPK).

Phase 2: HIF-1α Glycolytic Switch (2–12 h)

HIF-1α peaks to drive the Warburg switch: GLUT1 (SLC2A1), HK2, PFKFB3, ALDOA, PGK1, ENO1, PKM2, LDHA, and extracellular acidification via CAIX, CAXII, and MCT4 (SLC16A3).

Phase 3: HIF-2α Chronic Adaptation (24–72 h)

HIF-2α (EPAS1) accumulates to drive sustained angiogenesis (VEGFA, ANGPTL4), erythropoietin (EPO), lipid droplet storage (PLIN2), cancer stemness (OCT4, SOX2, CXCR4), and ECM remodeling (LOX/LOXL2).

Phase 4: Reoxygenation Resolution (0.5–24 h)

Upon reoxygenation, rapid pVHL-dependent degradation of HIF-α subunits occurs alongside an oxidative burst, permitting quantification of reperfusion recovery and inflammatory infiltration.

Hypoxia Research Scenarios and Experimental Designs

Research Scenario	Core Biological Question	Recommended Study Design & Readout
ccRCC & VHL Loss-of-Function	Evaluate constitutive HIF-2α oncogenic signaling and benchmark allosteric HIF-2α inhibitors (e.g., Belzutifan / MK-6482).	Factorial design: VHL-WT vs. VHL-KO ± Belzutifan dose-response; global DIA proteomics for target validation.
Tumor Core vs. Rim Gradients	Profile spatial metabolic adaptation and therapy resistance between necrotic hypoxic cores and vascularized tumor rims.	Laser-capture microdissected (LCM) tissue sections; high-sensitivity 4D-DIA (dia-PASeF) from 5×10⁴ cells.
Ischemia-Reperfusion (I/R) Models	Dissect acute ischemic protective adaptations from destructive oxidative reperfusion injury in stroke, myocardial infarction, or AKI.	Multi-arm time-course: Sham vs. Ischemia (Acute) vs. Reperfusion (0.5, 6, 24 h); paired phosphoproteomics + global DIA.
Hypoxic Secretome & Pre-Metastatic Niche	Identify paracrine angiogenic factors (VEGFA, ANGPTL4) and matrix cross-linkers (LOX, LOXL2, MMP2/9) priming metastatic niches.	Dual-layer profiling: whole-cell lysate + 12–24 h serum-free conditioned media secretome (3 kDa ultrafiltration).
HIF Degrader / PROTAC Discovery	Measure targeted degradation kinetics of HIF-1α or HIF-2α versus off-target proteome perturbations across time-courses.	Concentration- and time-dependent DIA profiling to determine DC₅₀, D_max, and proteome-wide selectivity.

Pre-Analytical Anti-Reoxygenation & Quenching SOP

Because room-air oxygen rapidly reactivates prolyl hydroxylases (HIF-α t_1/2 < 5 min), standard benchtop harvesting leads to severe artifactual HIF degradation. Creative Proteomics enforces strict anti-reoxygenation protocols:

Rapid Cold Quenching (≤15 s): Monolayers are removed from the hypoxia chamber directly onto ice, culture media aspirated immediately, and cells washed with ice-cold PBS within 15 seconds to halt enzymatic activity.
Direct On-Plate Denaturing Lysis: Cells are lysed directly on culture dishes using 5% SDS extraction buffer supplemented with protease, phosphatase (PhosSTOP, sodium orthovanadate), and deubiquitinase inhibitors to lock HIF-α in its native stabilized state.
Hypoxia Workstation Glove-Box Option: For ultra-sensitive PTM and interactome studies, sample scraping, washing, and lysis can be performed entirely within an enclosed hypoxia glove-box workstation at matched O₂ tension.
Serum-Free Secretome Pulse: For secretome analysis, cells are conditioned in defined serum-free medium for 12–24 h prior to harvest, clarified at 2,000 × g, and concentrated via 3 kDa ultrafiltration to eliminate bovine serum albumin (BSA) interference.

Analytical & Mass Spectrometry Platform Selection Guide

Match your hypoxia sample type, cohort scale, and biological question with the optimal acquisition strategy and mass spectrometry platform.

Study Objective & Scenario	Recommended Strategy	Primary MS Platform	Technical Rationale & Deliverables
Global Hypoxic Adaptation & Glycolysis (In Vitro Cancer Models / 2D & 3D Cultures)	Discovery DIA Quantitative Proteomics	Orbitrap Astral / Exploris 480 / timsTOF Pro 2	Single-shot depth (>6,500–8,500+ proteins), CV < 15%, deep coverage of Warburg glycolytic enzymes, CAIX, and lipid droplet factors.
Microscale & Spatially Resolved Samples (Microdissected Tumor Cores / Needle Biopsies)	High-Sensitivity 4D-DIA (dia-PASeF)	timsTOF Pro 2 / timsTOF Ultra	TIMS ion mobility maximizes ion utilization and peak capacity, enabling deep quantification from as few as 5×10⁴ to 2×10⁵ cells (500 ng – 2 μg protein).
Acute Stress Kinase & Signaling Kinetics (0.5–6 h Time-Course / Reoxygenation)	4D Phosphoproteomics (Ti-IMAC / Fe-NTA Enrichment)	timsTOF Pro 2 (TIMS-DIA) / Orbitrap Exploris 480	Resolves isomeric phosphopeptides, localizes regulatory phosphosites (>15,000–25,000+ sites), and drives KSEA stress kinase activity inference (AMPK/PERK/MAPK).
Paracrine Angiogenesis & ECM Remodeling (Serum-Free Conditioned Media Supernatants)	Hypoxic Secretome DIA Profiling	Orbitrap Exploris 480 / timsTOF Pro 2	High dynamic range resolves low-abundance secreted angiogenic factors (VEGFA, ANGPTL4), LOX/LOXL2, and MMPs following 3 kDa ultrafiltration cleanup.
HIF Inhibitor & Target Validation Panels (Belzutifan / PROTACs / Screening Cohorts)	Targeted PRM / 4D-PRM Panels	Orbitrap PRM / Triple Quadrupole (TSQ Altis / QTRAP 6500+)	Absolute or high-precision relative quantification of curated 20–60 hypoxia marker panels with high throughput and zero missing values across cohorts.

Sample Submission Requirements

Sample Category	Recommended Input	Minimum Feasibility	Harvesting & Shipping Guidelines
Standard Cell Pellets (Global DIA)	1–5 × 10⁶ cells (20–50 μg protein)	2 × 10⁵ cells (≥2 μg protein)	Wash 2× with ice-cold PBS (≤15 s); aspirate completely; flash-freeze pellet in liquid N₂. Ship on dry ice (-80°C).
Fresh-Frozen Tissues (Tumor / I/R)	20–50 mg wet weight	5 mg wet weight	Dissect rapidly (≤30 s post-euthanasia); snap-freeze immediately in liquid N₂. Ship on dry ice (-80°C).
Microscale / Sorted Cells (FACS / LCM)	1–5 × 10⁵ sorted cells (1–5 μg protein)	5 × 10⁴ cells (~500 ng protein)	Sort directly into low-binding tubes with lysis buffer or flash-freeze dry pellet in liquid N₂. Ship on dry ice.
Hypoxia Phosphoproteomics	5–10 × 10⁶ cells (100–200 μg protein)	50 μg total protein	Immediate on-plate lysis in buffer with PhosSTOP & 1 mM sodium orthovanadate; flash-freeze. Ship on dry ice.
Conditioned Media (Secretome)	2–5 mL conditioned medium per replicate	1 mL medium	Serum-free conditioning (12–24 h); clarify at 2,000 × g (10 min); flash-freeze supernatant in cryovials. Ship on dry ice.
Pre-Extracted Lysates	20–50 μL at 1–2 mg/mL	5 μg total protein	SDS/RapiGest buffer; BCA quantified; document lysis buffer composition. Ship on dry ice.

Deliverables and Decision-Ready Outputs

Quantitative data tables, quality documentation, and biological interpretation

PCA and UMAP clustering of normoxic, hypoxic, and reoxygenated states

Sample-level PCA/UMAP assesses whether quantitative profiles organize according to normoxic, acute hypoxic, and chronic hypoxic states.

Warburg glycolysis and hypoxic secretome heatmap

Hierarchical clustering identifies coordinated enzyme modules across glycolysis, pH regulation, lipid droplets, and angiogenesis.

Volcano plot of differential protein abundance in hypoxia

Pairwise contrasts (Hypoxia vs. Normoxia, Hypoxia ± Belzutifan) prioritize significant hypoxia biomarkers and therapeutic targets.

GSEA pathway enrichment and KSEA kinase network in hypoxia

GSEA pathway enrichment and KSEA kinase networks provide deep mechanistic context for HIF signaling cascades and metabolic shifts.

Discuss Your Project

Quantitative Data Tables

Normalized protein-, peptide-, and phosphosite-level intensity matrices with complete experimental annotations.

Quality Assessment Summary

Sample-level review, digestion completeness metrics, pooled QC CV distributions, and batch reproducibility reports.

Comparative & Temporal Analysis

Pairwise statistical contrasts, Benjamini-Hochberg FDR correction, and HIF-1α vs. HIF-2α temporal trajectory scorecards.

Pathway & Kinase Networks

Gene Ontology (GO), KEGG, and Reactome GSEA enrichment, plus KSEA stress kinase-substrate network mapping.

Bioinformatics & Reporting

Comprehensive final project report with publication-ready figures and prioritized targeted PRM validation candidate shortlists.

Hypoxia Proteomics Frequently Asked Questions

How do you prevent HIF-α degradation and reoxygenation artifacts during cell harvesting?

HIF-1α and HIF-2α subunits possess an extremely short half-life (<5 minutes) upon exposure to atmospheric oxygen due to rapid PHD reactivation and VHL-mediated ubiquitination. We implement strict anti-reoxygenation SOPs: (1) rapid ice-cold PBS washing (≤15 seconds total) followed immediately by direct on-plate lysis with SDS-based denaturing buffers containing protease and phosphatase inhibitors; or (2) cell scraping and lysis conducted directly inside a hypoxia workstation/glove box under matched O₂ tension.

What is the difference between physical hypoxia chambers and chemical hypoxia mimetics?

Physical hypoxia chambers (0.1%–1% O₂) mimic genuine in vivo physiological and pathological low-oxygen conditions, triggering authentic HIF stabilization, metabolic reprogramming, and translational adaptation. Chemical mimetics (CoCl₂, DMOG, DFO, Roxadustat) stabilize HIF by inhibiting PHDs via iron competition or 2-oxoglutarate antagonism; however, they cause broad off-target inhibition of other 2-oxoglutarate-dependent dioxygenases (such as histone lysine demethylases / KDMs and TET DNA demethylases). We recommend physical chamber control for physiological accuracy, and provide comparative benchmarking when chemical mimetics are evaluated.

How does proteomics distinguish acute HIF-1α responses from chronic HIF-2α signaling?

HIF-1α and HIF-2α exhibit distinct temporal dynamics and transcriptional target preferences. HIF-1α peaks during acute hypoxia (2–12 h) and predominantly drives glycolytic enzyme upregulation (GLUT1, HK2, LDHA, PDK1) and pH regulation (CAIX). In contrast, HIF-2α accumulates and remains stabilized during chronic hypoxia (24–72+ h), preferentially driving angiogenesis (VEGFA, ANGPTL4), erythropoiesis (EPO), iron transport (TFRC), and cancer stemness (OCT4, SOX2, CXCR4). Our multi-time-point DIA proteomic profiling tracks these distinct regulatory waves across time-course series.

What is the minimum cell number required for hypoxia DIA proteomics?

For standard global DIA whole-cell proteomics, we recommend 1–5 × 10⁶ cells (yielding 20–50 μg protein), though robust data can be acquired from 2 × 10⁵ cells. For precious samples (e.g., laser-capture microdissected hypoxic tumor cores, 3D organoid spheroids, or needle biopsies), our high-sensitivity 4D-DIA (dia-PASeF on timsTOF Pro 2) routinely quantifies >5,500+ proteins from as few as 5 × 10⁴ cells (~500 ng protein). For phosphoproteomics, a minimum of 50–100 μg total protein is recommended.

How does proteomics evaluate HIF-2α inhibitor therapeutics (e.g., Belzutifan / MK-6482)?

Small-molecule HIF-2α allosteric inhibitors (such as Belzutifan in clear cell renal cell carcinoma / ccRCC) disrupt the heterodimerization between HIF-2α (EPAS1) and HIF-1β (ARNT), preventing transcription of downstream oncogenic programs. Our platform quantifies proteome-wide on-target and off-target shifts, measuring the selective downregulation of HIF-2α targets (VEGFA, CCND1, CXCR4, EGLN3) versus unaffected baseline housekeeping proteomes across dose- and time-dependent treatment cohorts.

Can hypoxia secretome analysis profile paracrine pro-angiogenic factors?

Yes. Tumor and stromal cells exposed to hypoxia secrete a rich repertoire of pro-angiogenic cytokines (VEGFA, bFGF, ANGPTL4), extracellular matrix cross-linkers (LOX, LOXL2), and matrix metalloproteinases (MMP2, MMP9) that prime the pre-metastatic niche. We implement a 12–24 h serum-free conditioning pulse followed by 3 kDa ultrafiltration cleanup to identify and quantify secreted effector proteins without bovine serum albumin (BSA) masking.

Can you profile ischemia-reperfusion (I/R) tissue models?

Yes. We process fresh-frozen tissues from animal models of acute myocardial infarction, ischemic stroke (MCAO), and renal ischemia-reperfusion injury. Our multi-group experimental designs compare Sham, Ischemia (Acute Hypoxia), and Reperfusion (Reoxygenation) phases to dissect protective HIF-mediated adaptations from oxidative reperfusion damage and inflammatory infiltration.

What sample submission format and project metadata are required?

Samples should be submitted as flash-frozen cell pellets (washed 2× with ice-cold PBS), fresh-frozen tissue pieces (≥20–50 mg), clarified conditioned media, or client-prepared protein lysates. Please provide project metadata including: (1) species (human/mouse/rat), (2) hypoxia model (O₂ chamber percentage, duration, chemical stabilizers), (3) normoxic/reoxygenation controls, (4) replicate mapping, (5) cell count or protein concentration, and (6) requested analytical layers (global DIA, 4D-phosphoproteomics, secretome).

* For Research Use Only. Not for use in the treatment or diagnosis of disease.

Online Inquiry

Please submit a detailed description of your project. We will provide you with a customized study plan to meet your requests. You can also send us an email to for inquiries.